ATLASATLAS fair value
CHF 177.09
Below fair value · 59% discount
Range: CHF 127–CHF 247Fair valuePrice
Basilea Pharmaceutica (BSLN.SW)
Basilea Pharmaceutica stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · SIX Swiss Exchange · Switzerland
CHF 72.20▲ +4.79%
Prices as of Oct 27, 2026 · CHF
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Basilea Pharmaceutica in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Basilea Pharmaceutica
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Basilea Pharmaceutica's fair value at about CHF 177.09 per share (reasonable range: CHF 127.17 to CHF 246.60). At CHF 72.20, the stock trades 59% below it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Basilea Pharmaceutica a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CHF 68.06 and CHF 76.71; in 9 out of 10, between CHF 61.21 and CHF 85.30. Estimated annual volatility is 36%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- CHF 831M
- Market cap (USD)
- $1.0B
- P/E ratio
- 16.7
- 52-week high
- CHF 75.80
- 52-week low
- CHF 44.70
- Revenue (12 months)
- CHF 247M
- Gross margin
- 38.5%
- Operating margin
- 26.9%
- Net margin
- 21.2%
- Beta
- 0.37
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Basilea Pharmaceutica sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks BSLN.SW has traded between CHF 44.70 and CHF 75.80. Today it is 4.8% below that high and 62% above its low.
On the business: net margin is 21.2%; it trades at 16.7 times earnings.
Its beta is 0.37: it tends to move less than the market.
About the company
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
Want to see everything about Basilea Pharmaceutica?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Basilea Pharmaceutica (BSLN.SW) fair value?
About CHF 177.09 per share according to ATLAS (reasonable range: CHF 127.17 to CHF 246.60). With the stock at CHF 72.20, it is 59% below it.
What is the chance BSLN.SW goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, BSLN.SW ends the month between CHF 68.06 and CHF 76.71.
How big is Basilea Pharmaceutica and what is its P/E ratio?
Basilea Pharmaceutica's market capitalization is CHF 831M. Its price-to-earnings (P/E) ratio is 16.7: you pay CHF 16.7 for each CHF 1.00 of yearly earnings.
How volatile is BSLN.SW?
ATLAS estimates annual volatility at 36%. In a typical month, half of the outcomes end between CHF 68.06 and CHF 76.71.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer